Connect with us

Menopause

Menopause stigma still ‘rife’ in the workplace, research reveals

Nearly half of women said they would lie about why they needed a sick day to cover up menopause symptoms

Published

on

Women are hiding their menopause symptoms to avoid discrimination in the workplace, new research has found, with nearly half of female employees fearing that menopause would affect their careers.

The survey, conducted by the law firm Lime Solicitors, has shown that despite increased awareness around menopause, women are still embarrassed to discuss the topic at work.

The report has found that 48 per cent of respondents said they would lie about why they needed a sick day, with 39 per cent admitting that they felt embarrassed to talk about menopause at work.

Despite it being their right, less than a third (29 per cent) of women said they would feel comfortable asking for reasonable adjustments to support symptoms while less than half (49 per cent) said they would feel able to raise a formal complaint if they felt they were being discriminated against as a result of experiencing menopause.

“Our research shows that almost half of women surveyed think that going through menopause will negatively impact their career, which is why so many women suffer in silence,” said Neha Thethi, head of employment at Lime Solicitors.

“It appears that employers are failing an important part of their workforce by not providing the necessary support or creating a positive culture whereby people can raise concerns or issues with confidence.”

The law firm has found that lack of flexibility is a barrier, with over a third of women reporting that menopausal symptoms would prevent them from re-entering the workforce.

With as many as 60 per cent of participants saying their workplace should offer additional menopause support, employment law experts at Lime Solicitors are calling for the implementation of menopause champions in all workplaces to raise awareness of the menopause impacts women in the workplace and ensure that all women know their rights.

“To help dispel the stigma around menopause and empower women to speak freely and honestly about their experiences, we need menopause champions in all workplaces,” said Thethi.

“Not only will this help women feel more comfortable raising a complaint, but it will also ensure that employers know how to offer the right support from the start, supporting both retention and attraction of experienced women.

“Discrimination expresses itself in many forms and if a woman has ever felt discriminated against in the workplace, she should consider escalating the matter.

“While menopause itself is not a protected characteristic, there are still legal protections in place that women can rely on to safeguard against discrimination. Under the Equality Act, women can bring a sex, age, or disability claim if they think their employer has fallen foul of their obligations.”

News

Smartwatch data helps researchers study menopause transition

Published

on

Smartwatch data may help track menopause sleep changes after researchers analysed more than 94,000 nights of Apple Watch sleep records.

The study analysed more than 94,000 nights of sleep data from 338 participants in the Apple Women’s Health Study.

It found that many participants spent more time awake during the night in the 12 months before and after their final logged menstrual period.

For the past several years, Apple has used the Apple Watch to support large-scale health studies through the Apple Research app.

These include the Apple Women’s Health Study, the Apple Heart and Movement Study, and the Apple Hearing Study, which launched in 2019 with research partners including Harvard, Brigham and Women’s Hospital, the American Heart Association and the University of Michigan.

In February 2025, Apple said those studies had grown to more than 350,000 participants across the US.

Recently, researchers at Harvard T.H. Chan School of Public Health published results on how sleep patterns change during perimenopause.

The study looked at wake after sleep onset, or WASO, which measures how much time a person spends awake after first falling asleep.

In the 18 months leading up to menopause, 60 per cent of women with sleep tracking data showed increased WASO compared with the previous six months.

The average increase was 7 per cent.

Researchers also found that, in the 12 months before and after the last logged menstrual period, participants spent about 0.8 per cent more of their sleep time awake after menopause than before.

However, the findings varied widely between participants.

Some women had much larger increases in time awake after menopause, while others had no meaningful sleep change at all.

The researchers said this reflects the fact that each person experiences perimenopause and menopause differently.

Participants who tracked sleep also logged menopause symptoms.

Hot flushes were reported by 82.3 per cent of participants, irritability by 68.1 per cent, mental exhaustion by 65.7 per cent and sexual symptoms by 65.6 per cent.

Among participants with more severe menopause symptoms, the symptoms most closely linked with worse sleep were bladder symptoms, joint symptoms, heart discomfort and depressive symptoms.

The researchers also shared recommendations that may help women sleep better during perimenopause.

These include maintaining a cool sleeping environment, keeping a consistent sleep schedule, getting regular movement, avoiding common bladder irritants and limiting fluids in the hours before bedtime, and prioritising relaxation or mindfulness techniques as part of a bedtime routine.

Continue Reading

News

Women still being failed when they reach menopause, experts say

Published

on

Women are still being failed by menopause care despite a surge in online advice, with experts saying symptoms are too often minimised or dismissed.

The researchers exposed a gap between the surge of menopause information available online and the quality of medical care women receive.

A team of anthropologists and psychologists explored the physical and emotional toll of menopause, including its impact on work and personal lives, through interviews with 60 women aged 45 to 61 between March and June 2021.

The findings were published in a new book, We Need to Talk About Menopause.

The interviews showed how women continue to “needlessly suffer” as they sort through misinformation from influencers, celebrities and so-called experts.

The authors said: “You would think in an age where humans are developing commercial space flight, self-driving cars, and AI personal assistants who can project movies onto the palm of your hand, we would understand more about menopause, something a little over half of the population is guaranteed to experience in their lives.”

The interviews revealed wide variation in women’s experiences of doctors.

Some felt they could have an open dialogue, while others said they were “shut down”, including being told they were too young for menopause.

One woman said she bled heavily for a year before she was taken seriously.

The authors said menopause is still poorly understood, with disagreement over whether it should be seen as a medical condition or a natural part of ageing.

There are more than 100 recognised symptoms, although some women experience none.

Among those interviewed, 78 per cent reported weight gain and redistribution, particularly around the belly area, which was resistant to diet and exercise.

Fifty-eight per cent experienced mood disturbances including anxiety, depression, irritability and unprecedented levels of rage.

Many women said they were blindsided by symptoms they had never known existed.

One participant said she only realised rage was a menopause symptom after seeing it mentioned in a television commercial.

Women also described severe memory problems and brain fog that colleagues mistook for incompetence, leading successful professionals to question their abilities at the peak of their careers.

Brain fog can include problems with concentration, memory and clear thinking.

According to Statistics Canada, 70 per cent of women turn to the internet as their primary source of menopause information.

The authors said this information vacuum has spawned a £14.7bn global “meno-tech” industry, with influencers, celebrities and telehealth companies offering products ranging from £98 creams to unnecessary blood tests.

They said: “The growth of interest in menopause has also been accompanied by a wave of unsubstantiated information.

“Many websites market expensive creams, supplements, and weight-loss schemes that promise to keep women youthful and attractive, with little evidence to support their claims.

“Reliable, accessible information about menopause and perimenopause is still lacking. Despite increased attention to the importance of physician training and the search for menopause specialists, the medical profession as a whole continues to provide limited support in this area.”

The authors also highlighted the effect of menopause in the workplace.

The House of Commons Women and Equalities Committee has warned that Britain is “haemorrhaging talent” because of menopause, with 14 million workdays lost each year, according to the Office for National Statistics.

Despite this, studies have shown 80 per cent of UK employers have yet to implement proper support measures for menopausal women.

Some women said simple workplace adjustments made a significant difference.

Continue Reading

Menopause

Sweden eyes domestic production of oestrogen patches amid menopause treatment shortage

Published

on

Sweden is exploring domestic production of oestrogen patches as shortages continue to disrupt menopause treatment.

Two government agencies have been asked to examine whether transdermal oestrogen patches could be made in the country.

Transdermal treatments deliver medicine through the skin, most commonly through patches, gels or sprays. They provide a continuous low dose of hormones.

The move follows a long-running shortage of oestrogen treatments that has left women struggling with menopause symptoms and forced pharmacists to look for alternatives.

Hot flushes, mood swings and depression are among the well-documented effects of menopause.

Jakob Forssmed, the health and social affairs minister, has asked the Swedish Medical Products Agency and the Dental and Pharmaceutical Benefits Agency to examine whether the patches could be produced in Sweden.

Speaking to Dagens Nyheter, Forssmed described the assignment as “very urgent”, citing recurring shortages affecting women who “need these medications to lead a functional life”.

The Swedish Medical Products Agency will examine whether a national operator could produce bulk transdermal formulations of oestrogen medicines and, where possible, prepare a process for production.

One possible manufacturer is the state-owned Apotek, Produktion & Laboratorier, which makes medicines tailored to the needs of the Swedish health system.

In 2025, about 205,000 women aged over 45 in Sweden were using systemic oestrogen treatment, according to a report from the Board of Health and Welfare.

That represents 8 per cent of women in the age group.

Transdermal oestrogen has become increasingly popular among menopausal women in Sweden. When patches are unavailable, some women switch to sprays and gels, which can then also run out of stock.

There is no shortage of oestrogen pills. However, experts say they are not a suitable option for everyone because of side effects that patches, sprays and gels do not have.

Angelica Lindén Hirschberg, professor of obstetrics and gynaecology at Karolinska Institutet, told Läkemedelsvärlden: “The pills affect the liver’s production of proteins and increase the risk of blood clots. For many women, the transdermal option, administered through the skin, is the only medically appropriate choice.”

Demand for hormone treatment has risen sharply in Sweden and globally, contributing to shortages.

Manufacturing constraints, supply chain bottlenecks and rising production costs are also said to play a role.

Läkemedelshandlarna, the Swedish association for parallel importers, has said access could be improved by allowing importers to buy hormone patches from other European countries at higher prices.

In response, representatives of the Swedish Medical Products Agency and the Dental and Pharmaceutical Benefits Agency said the causes of shortages needed to be seen “in a more nuanced light”.

They said: “The price level in Sweden is not the only explanation for the shortage of transdermal oestrogens, that is, oestrogen medications administered through the skin, most commonly via patches, gels, or sprays.

“Increased global demand and production issues are also affecting international supply.”

Estradot is among the oestrogen patches affected by shortages.

Some dosage strengths have been removed from Swedish benefit schemes by manufacturer Sandoz after authorities did not approve higher prices.

Under the government’s instruction, the Medical Products Agency will also consider whether access could be secured through EU mechanisms, including public procurement.

The Dental and Pharmaceutical Benefits Agency will examine whether more companies could hold marketing authorisations for transdermal oestrogen medicines, as well as whether parallel trade could be promoted.

The agencies are due to report back to the government by 30 October.

The Board of Health and Welfare report also found disparities in access to hormone patches across areas with different socioeconomic conditions.

In areas facing major socioeconomic challenges, 3.2 per cent of women collected hormone replacement therapy. In areas with very good socioeconomic conditions, the figure was 12.1 per cent.

Maja Österlund, an investigator at the agency, said: “These differences reflect a healthcare system that is currently unequal, and where we also know there is a shortage of certain medicines.”

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.